THRIVE Drug Patent Profile
✉ Email this page to a colleague
When do Thrive patents expire, and when can generic versions of Thrive launch?
Thrive is a drug marketed by Glaxosmithkline Cons and is included in two NDAs.
The generic ingredient in THRIVE is nicotine polacrilex. There are thirty drug master file entries for this compound. Sixty suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Thrive
A generic version of THRIVE was approved as nicotine polacrilex by P AND L on March 15th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for THRIVE?
- What are the global sales for THRIVE?
- What is Average Wholesale Price for THRIVE?
Summary for THRIVE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Clinical Trials: | 47 |
| DailyMed Link: | THRIVE at DailyMed |
Recent Clinical Trials for THRIVE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cairo University | Phase 4 |
| Imperial College London | Phase 4 |
| Viridian Therapeutics, Inc. | Phase 3 |
US Patents and Regulatory Information for THRIVE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077658-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077656-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
